Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 2/20 | 0.51 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9868828 | 0.90 | SCN1A (0.44) | SCN1ASCN2ASCN3ACXCR4HRH3 | |
| SCHEMBL10192095 | 0.80 | SCN1A (0.52) | SCN1ASCN2ASCN3ACXCR4HRH3 | |
| SCHEMBL23828669 | 0.78 | CXCR4 (0.57) | SCN1ASCN2ASCN3ACXCR4HRH3 | |
| SCHEMBL30603861 | 0.78 | CXCR4 (0.57) | SCN1ASCN2ASCN3ACXCR4HRH3 | |
| SCHEMBL2115515 | 0.75 | CXCR4 (0.51) | SCN1ASCN2ASCN3ACXCR4HRH3 | |
| SCHEMBL25840372 | 0.75 | SCN1A (0.49) | SCN1ASCN2ASCN3ACXCR4HRH3 | |
| SCHEMBL25840370 | 0.75 | SCN1A (0.49) | SCN1ASCN2ASCN3ACXCR4HRH3 | |
| SCHEMBL26786943 | 0.75 | HRH3 (0.54) | SCN1ASCN2ASCN3ACXCR4HRH3 | |
| SCHEMBL25840373 | 0.75 | SCN1A (0.49) | SCN1ASCN2ASCN3ACXCR4HRH3 | |
| SCHEMBL26786966 | 0.75 | HRH3 (0.54) | SCN1ASCN2ASCN3ACXCR4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387307-A1 | METHOD OF TREATING DISEASE | CREWS THOMAS M (US) | 2022-12-08 | — | — | US | disclosed |
| US-11123284-B2 | Method of treating disease | CREWS THOMAS M (US) | 2021-09-21 | — | — | US | disclosed |
| US-9968589-B2 | Method of treating disease by auricular anesthesia of cranial nerves | CREWS THOMAS M (US) | 2018-05-15 | — | — | US | disclosed |
| US-9968589-B2 | Method of treating disease by auricular anesthesia of cranial nerves | CREWS THOMAS M (US) | 2018-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387307-A1 | METHOD OF TREATING DISEASE | COXFA4L2, ASAH2, OTC | SCN1A 1405/4885SCN2A 2081/4885SCN3A 1010/4885 |
| US-11123284-B2 | Method of treating disease | COXFA4L2, ASAH2, OTC | SCN1A 1405/4885SCN2A 2081/4885SCN3A 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.